Skip to main content
Premium Trial:

Request an Annual Quote

FDA Adopts Pharsight Simulation Program for HIV Drug Development

NEW YORK, Feb. 25 (GenomeWeb News) - The US Food and Drug Administration has used a quantitative-based modeling and simulation program designed by Pharsight to help it design an end-of-Phase IIa trial for an anti-HIV drug, Pharsight said today.

 

The relationship between Pharsight and the FDA is partly the result of the agency's EOPIIa program, which is part of the Critical Path Initiative. The program enables the FDA to provide sponsors of clinical trials with input earlier in the drug-development cycle.

 

Pharsight said it believes that quantitative-based modeling and simulation during drug development can increase the productivity and efficiency of the process.

The Scan

Wolf Howl Responses Offer Look at Vocal Behavior-Related Selection in Dogs

In dozens of domestic dogs listening to wolf vocalizations, researchers in Communication Biology see responses varying with age, sex, reproductive status, and a breed's evolutionary distance from wolves.

Facial Imaging-Based Genetic Diagnoses Appears to Get Boost With Three-Dimensional Approach

With data for more than 1,900 individuals affected by a range of genetic conditions, researchers compared facial phenotype-based diagnoses informed by 2D or 3D images in the European Journal of Human Genetics.

Survey Suggests Multigene Cancer Panel VUS Reporting May Vary Across Genetic Counselors

Investigators surveyed dozens of genetic counselors working in clinical or laboratory settings, uncovering attitudes around VUS reporting after multigene cancer panel testing in the Journal of Genetic Counseling.

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.